SOURCE: Alzheimer's Drug Discovery Foundation

October 29, 2007 13:14 ET

Alzheimer's Drug Discovery Foundation Appoints New Managing Director and Chief Operating Officer

NEW YORK, NY--(Marketwire - October 29, 2007) - The Alzheimer's Drug Discovery Foundation (ADDF) appointed Catherine Camera to the new position of Managing Director and Chief Operating Officer. Ms. Camera comes to the ADDF with over 25 years of executive management experience in a variety of industries.

As noted by ADDF Executive Director Howard Fillit, MD, "We are very excited to have the opportunity to work with Catherine. She brings extensive knowledge from the corporate, university and philanthropic sectors to our foundation. We are looking forward to working with Catherine to advance drug discovery for Alzheimer's disease."

Dr. Fillit's sentiments were echoed by ADDF Board Co-Chairperson Leonard Lauder, Chairman of The Estée Lauder Companies, who stated, "We are thrilled to have Catherine join the ADDF. Her extraordinary background combined with her passion and dedication to finding a cure for Alzheimer's disease makes her an ideal leader to help us expand our foundation and build our partnership base with the public."

Prior to joining ADDF, Ms. Camera served as president of Philanthropy Plus, a consulting and marketing firm specializing in fundraising services for non-profit organizations. During her career, she held numerous leadership positions including Executive Vice President of Operations for Career Horizons and Associate Vice President of Alumni Relations and Development at St. John's University in New York. Ms. Camera serves on the Boards of the St. John's University School of Business Alumni, Child Abuse Prevention Services and the Fire Department of New York Foundation.

About the Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998. Our mission is to accelerate drug discovery research for Alzheimer's disease, related dementias and cognitive aging through venture philanthropy. To date, ADDF and ISOA have awarded $28.7 million for 195 research programs and conferences worldwide. For more information, visit

Contact Information